
Stimdia Medical
Developer of a lung pacing device intended to facilitate weaning patients from mechanical ventilation.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | $16.1m | Series B | |
Total Funding | 000k |
Related Content
Stimdia Medical specializes in developing advanced medical devices aimed at aiding mechanically ventilated patients in weaning off ventilators. The company's flagship product, the pdSTIM System, employs a minimally invasive method to temporarily stimulate the phrenic nerve, facilitating diaphragmatic function and improving patient outcomes. Stimdia Medical primarily serves healthcare providers and hospitals, focusing on adult patients who have been on mechanical ventilation for extended periods and have failed weaning attempts. Operating in the medical device market, the company generates revenue through the sale of its pdSTIM System and related services. Stimdia Medical's business model includes direct sales and partnerships with healthcare institutions. The company is committed to innovation and has made significant advancements, including the initiation of pivotal clinical studies and strategic growth initiatives.
Keywords: phrenic nerve stimulation, mechanical ventilation, weaning, diaphragmatic function, minimally invasive, healthcare, medical devices, clinical studies, innovation, patient outcomes.